BUSINESS4 years ago
Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) Publishes Phase 2b Lenabasum Study In Cystic Fibrosis In The Cystic Fibrosis Journal
Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) has announced its baseline patient disease characteristics and demographics in the Phase 2b lenabasum study in cystic fibrosis. The company has also...